ProShare Advisors’s Viking Therapeutics VKTX Stock Holding History

ProShare Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,716	Closed	-$727K	–	2112
2024 Q2	$727K	Sell	13,716 -4,686	-25%	-$307K	﹤0.01%	821
2024 Q1	$1.51M	Buy	18,402 +2,487	+16%	+$111K	﹤0.01%	708
2023 Q4	$296K	Buy	15,915 +3,424	+27%	+$44.8K	﹤0.01%	1392
2023 Q3	$138K	Sell	12,491 -14	-0.1%	-$200	﹤0.01%	1568
2023 Q2	$203K	Buy	+12,505	New	+$262K	﹤0.01%	1533
2022 Q2	–	Sell	-12,825	Closed	-$39K	–	2140
2022 Q1	$39K	Sell	12,825 -2,122	-14%	-$7.61K	﹤0.01%	2130
2021 Q4	$69K	Buy	+14,947	New	+$83.8K	﹤0.01%	2245
2021 Q3	–	Sell	-17,747	Closed	-$106K	–	2279
2021 Q2	$106K	Buy	17,747 +223	+1%	+$1.32K	﹤0.01%	2284
2021 Q1	$111K	Buy	17,524 +2,998	+21%	+$21.1K	﹤0.01%	2153
2020 Q4	$82K	Buy	+14,526	New	+$88K	﹤0.01%	2012

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

ProShare Advisors's VKTX Position: Q3 2024 in Review

ProShare Advisors sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 13,716 shares — an estimated $727K sold.

ProShare Advisors first reported a position in VKTX in Q4 2020 and held it in 10 quarters. The position peaked at $1.51M in Q1 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

ProShare Advisors reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
ProShare Advisors sold 13,716 Viking Therapeutics shares in Q3 2024, an estimated $727K.
ProShare Advisors first reported a position in Viking Therapeutics in Q4 2020 and held it in 10 quarters.
ProShare Advisors's Viking Therapeutics position peaked at $1.51M in Q1 2024.
422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on ProShare Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.